Although alteplase is indicated for treatment of acute massive PE, many patients cannot receive systemic thrombolysis due to contraindications, and even when patients with acute PE are prescreened for absolute contraindications, the rate of major hemorrhage from systemic thrombolytic administration is approximately 20%, including a 3%5%% risk of hemorrhagic stroke [ 3].
It is also associated with increased myocardial perfusion, decreased major hemorrhage, and mortality.
To identify clinical markers of severity in dengue, different from those of major hemorrhage.
A major hemorrhage and swelling were putting pressure on his brain.
No CSF leak or major hemorrhage was noted using this endonasal approach, and no concerning postoperative sequelae were encountered.
The primary efficacy end point was stroke or systemic embolism; the safety end point we studied was major hemorrhage.
To identify the risk ofthromboembolism after withholding or reversing the effect of warfarintherapy following a major hemorrhage.
There were no significant differences between the two groups in the rates of either stroke or major hemorrhage, leading Dr. Mohr to conclude that the drugs were equally effective.
Treatment consists of replacement of blood when there is a major hemorrhage, transfusion of platelets for emergency management, and, in selected cases, administration of adrenocortical steroids and removal of the spleen.
CONCLUSIONS: An indirect comparison of new anticoagulants based on existing trial data indicates that in patients with a CHADS(2) score >/=3 dabigatran 150 mg, apixaban 5 mg, and rivaroxaban 20 mg resulted in statistically similar rates of stroke and systemic embolism, but apixaban had a lower risk of major hemorrhage compared with dabigatran and rivaroxaban.
To compare confounding adjustment by high-dimensional propensity scores (hdPSs) and historically developed high-dimensional disease risk scores (hdDRSs) in three comparative study examples of newly marketed medications: (1) dabigatran vs. warfarin on major hemorrhage; (2) on death; and (3) cyclooxygenase-2 inhibitors vs. nonselective nonsteroidal anti-inflammatory drugs on gastrointestinal bleeds.
